Economic burden of severe asthma in Turkey: a cost of illness study from payer perspectiveS. Bavbek firstname.lastname@example.org, S. Malhan2, D. Mungan1, Z. Misirligil1, M. Erdinc3, B. Gemicioglu4,
I. Kivilcim Oguzulgen5, E. Oksuz6, F. Yildiz7, A. Yorgancioglu8Show more: Authors information and Publication history
Division of Immunology and Allergy, Department of Chest Diseases, School of Medicine, Ankara University, Ankara, Turkey2
Department of Health Care Management, Faculty of Medical Sciences, Baskent University, Ankara, Turkey3
Department of Chest Diseases, School of Medicine, Ege University, Izmir, Turkey4
Department of Pulmonary Diseases, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul, Turkey5
School of Medicine, Gazi University, Ankara, Turkey6
Department of Family Medicine, School of Medicine, Baskent University, Ankara, Turkey7
Department of Chest Diseases, School of Medicine, Dr. Suat GŁnsel University of Kyrenia Hospital, Kyrenia, Cyprus8
Department of Chest Diseases, School of Medicine, Celal Bayar University, Manisa, TurkeyHistory:
Published online: 26 April 2021
Accepted: 21 April 2020
Received: 12 January 2020
To estimate economic burden of severe asthma in Turkey from payer perspective based on expert panel opinion on practice patterns in clinical practice. Methods.
This cost of illness study was based on identification of per patient annual direct medical costs for the management of sever easthma in Turkey from payer perspective. Average per patient direct medical cost was calculated based on cost items related to outpatient visits, laboratory and radiological tests, hospitalizations and interventions, drug treatment and equipment, and co-morbidities/complications. Results.
Based on total annual per patient costs calculated for outpatient admission ($ 177.91), laboratory and radiological tests ($ 82.32), hospitalizations/interventions ($ 1,154.55), drug treatment/equipment ($ 2,289.63) and co-morbidities ($ 665.39) cost items, total per patient annual direct medical costrelated to management of severe asthma was calculated to be $ 4,369.76 from payer perspective. Drug treatment/equipment (52.4%) was the main cost driver in the management of severe asthma in Turkey, as followed by hospitalizations/interventions (26.4%) and co-morbidities (15.2%). Conclusions.
In conclusion, our findings indicate that managing patients with severe asthma pose a considerable burden to health economics in Turkey, with medications as the main cost driver. Key words
Severe asthma; asthma attack; practice patterns; direct costs; cost analysis; Turkey.
Cite this article as:
Bavbek S, Malhan S, Mungan D, Misirligil Z, Erdinc M, Gemicioglu B, Kivilcim Oguzulgen I, Oksuz E, Yildiz F, Yorgancioglu A, Economic burden of severe asthma in Turkey: a cost of illness study from payer perspective, Eur Ann Allergy Clin Immunol 2021;53(3):128-137. doi:10.23822/EurAnnACI.1764-1489.149.